drugset / Trial / NCT01297972

Mesenchymal Stem Cells in the Treatment of Relapsed/Refractory Severe Acquired Aplastic Anemia

NCT01297972

Phase 1/2 Completed 9 enrolled University of Sao Paulo
NaSingle-groupOpen-labelTreatment

Summary

Mesenchymal stem cells have been tested in many autoimmune disorders with encouraging results and may be an alternative to the treatment of immune-mediated severe acquired aplastic anemia.

Timeline

Start
2011-02
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy 2.7e+06 cells/kg Intravenous

Indications